Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy

[1]  G. Pawelec.  Immunosenescence and cancer , 2017, Biogerontology.

[2]  L. Nardo,et al.  Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. , 2016, The Journal of clinical investigation.

[3]  M. Vetizou,et al.  Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. , 2016, Immunity.

[4]  C. Berking,et al.  Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab , 2016, Clinical Cancer Research.

[5]  J. Wolchok,et al.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[6]  S. Moschos,et al.  Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. , 2016, Cancer treatment reviews.

[7]  E. Deeks.  Pembrolizumab: A Review in Advanced Melanoma , 2016, Drugs.

[8]  D. Schadendorf,et al.  Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab , 2016, Clinical Cancer Research.

[9]  T. Gajewski,et al.  Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. , 2016, Advances in immunology.

[10]  H. Maecker,et al.  Predictors of clinical response to immunotherapy with or without radiotherapy , 2015, Journal of Radiation Oncology.

[11]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[12]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[13]  Haidong Dong,et al.  A Gender Factor in Shaping T-Cell Immunity to Melanoma , 2015, Front. Oncol..

[14]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[15]  Maria L. Wei,et al.  Sex disparities in melanoma outcomes: the role of biology. , 2014, Archives of biochemistry and biophysics.

[16]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[17]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[18]  J. Lunceford,et al.  Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. , 2014 .

[19]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[20]  C. Meyer,et al.  Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab , 2014, Cancer Immunology, Immunotherapy.

[21]  C. Horak,et al.  Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Sullivan,et al.  The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be , 2013, Clinical Cancer Research.

[23]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[24]  A. Weaver,et al.  Gender differences in survival from cutaneous melanoma: Analysis of United States SEER data, 1992 to 2009. , 2013 .

[25]  C. Weyand,et al.  Understanding immunosenescence to improve responses to vaccines , 2013, Nature Immunology.

[26]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[27]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[28]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[29]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Vandenbark,et al.  Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). , 2007, International immunology.

[31]  A. Vandenbark,et al.  Estrogen‐mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD‐1 costimulatory pathway , 2006, Journal of neuroscience research.

[32]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[33]  J. Manola,et al.  Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.